INTERCEPT PHARMACEUTICALS IN (ICPT) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:ICPT • US45845P1084

19 USD
+0.04 (+0.21%)
At close: Nov 7, 2023
19 USD
0 (0%)
After Hours: 11/7/2023, 8:02:20 PM
Fundamental Rating

2

Taking everything into account, ICPT scores 2 out of 10 in our fundamental rating. ICPT was compared to 524 industry peers in the Biotechnology industry. ICPT has a bad profitability rating. Also its financial health evaluation is rather negative. ICPT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • ICPT had negative earnings in the past year.
  • In the past year ICPT has reported a negative cash flow from operations.
ICPT Yearly Net Income VS EBIT VS OCF VS FCFICPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 0 200M -200M -400M

1.2 Ratios

  • The Return On Assets of ICPT (-15.67%) is better than 84.91% of its industry peers.
  • Looking at the Return On Equity, with a value of -85.76%, ICPT is in line with its industry, outperforming 45.94% of the companies in the same industry.
Industry RankSector Rank
ROA -15.67%
ROE -85.76%
ROIC N/A
ROA(3y)-8.21%
ROA(5y)-26.21%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ICPT Yearly ROA, ROE, ROICICPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 -500 -1K -1.5K -2K

1.3 Margins

  • Looking at the Gross Margin, with a value of 99.80%, ICPT belongs to the top of the industry, outperforming 99.17% of the companies in the same industry.
  • ICPT's Gross Margin has been stable in the last couple of years.
  • ICPT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 99.8%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.45%
GM growth 5Y0.15%
ICPT Yearly Profit, Operating, Gross MarginsICPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • ICPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, ICPT has more shares outstanding
  • Compared to 1 year ago, ICPT has an improved debt to assets ratio.
ICPT Yearly Shares OutstandingICPT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M
ICPT Yearly Total Debt VS Total AssetsICPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M

2.2 Solvency

  • Based on the Altman-Z score of -5.03, we must say that ICPT is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -5.03, ICPT is not doing good in the industry: 66.17% of the companies in the same industry are doing better.
  • ICPT has a Debt/Equity ratio of 3.12. This is a high value indicating a heavy dependency on external financing.
  • The Debt to Equity ratio of ICPT (3.12) is worse than 85.41% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.12
Debt/FCF N/A
Altman-Z -5.03
ROIC/WACCN/A
WACC10.19%
ICPT Yearly LT Debt VS Equity VS FCFICPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 200M -200M 400M

2.3 Liquidity

  • A Current Ratio of 4.22 indicates that ICPT has no problem at all paying its short term obligations.
  • With a Current ratio value of 4.22, ICPT perfoms like the industry average, outperforming 42.45% of the companies in the same industry.
  • ICPT has a Quick Ratio of 4.22. This indicates that ICPT is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 4.22, ICPT is in line with its industry, outperforming 43.62% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.22
Quick Ratio 4.22
ICPT Yearly Current Assets VS Current LiabilitesICPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • The earnings per share for ICPT have decreased strongly by -125.05% in the last year.
  • Looking at the last year, ICPT shows a quite strong growth in Revenue. The Revenue has grown by 14.64% in the last year.
  • Measured over the past years, ICPT shows a quite strong growth in Revenue. The Revenue has been growing by 16.88% on average per year.
EPS 1Y (TTM)-125.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-98.97%
Revenue 1Y (TTM)14.64%
Revenue growth 3Y4.27%
Revenue growth 5Y16.88%
Sales Q2Q%14.44%

3.2 Future

  • Based on estimates for the next years, ICPT will show a very negative growth in Earnings Per Share. The EPS will decrease by -22.89% on average per year.
  • Based on estimates for the next years, ICPT will show a small growth in Revenue. The Revenue will grow by 1.71% on average per year.
EPS Next Y-122.07%
EPS Next 2Y-41.22%
EPS Next 3Y-33.62%
EPS Next 5Y-22.89%
Revenue Next Year3.67%
Revenue Next 2Y6.35%
Revenue Next 3Y4.21%
Revenue Next 5Y1.71%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ICPT Yearly Revenue VS EstimatesICPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M
ICPT Yearly EPS VS EstimatesICPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 5 -5 -10 -15

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ICPT. In the last year negative earnings were reported.
  • The Price/Forward Earnings ratio is 9.11, which indicates a very decent valuation of ICPT.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of ICPT indicates a rather cheap valuation: ICPT is cheaper than 99.00% of the companies listed in the same industry.
  • When comparing the Price/Forward Earnings ratio of ICPT to the average of the S&P500 Index (27.20), we can say ICPT is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 9.11
ICPT Price Earnings VS Forward Price EarningsICPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ICPT Per share dataICPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

  • ICPT's earnings are expected to decrease with -33.62% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-41.22%
EPS Next 3Y-33.62%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ICPT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

INTERCEPT PHARMACEUTICALS IN

NASDAQ:ICPT (11/7/2023, 8:02:20 PM)

After market: 19 0 (0%)

19

+0.04 (+0.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)02-29
Inst Owners0.17%
Inst Owner Change0%
Ins Owners10.38%
Ins Owner Change0%
Market Cap794.39M
Revenue(TTM)317.68M
Net Income(TTM)-61.61M
Analysts70
Price Target19.38 (2%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)95.4%
Min EPS beat(2)73.02%
Max EPS beat(2)117.78%
EPS beat(4)2
Avg EPS beat(4)-7.36%
Min EPS beat(4)-203.66%
Max EPS beat(4)117.78%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.75%
Min Revenue beat(2)-1.65%
Max Revenue beat(2)3.15%
Revenue beat(4)1
Avg Revenue beat(4)-2.32%
Min Revenue beat(4)-7.75%
Max Revenue beat(4)3.15%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.63%
PT rev (3m)24.59%
EPS NQ rev (1m)0%
EPS NQ rev (3m)660.22%
EPS NY rev (1m)0%
EPS NY rev (3m)3.74%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.01%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.24%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 9.11
P/S 2.5
P/FCF N/A
P/OCF N/A
P/B 11.06
P/tB 11.06
EV/EBITDA N/A
EPS(TTM)-1.33
EYN/A
EPS(NY)2.09
Fwd EY10.98%
FCF(TTM)-1.5
FCFYN/A
OCF(TTM)-1.51
OCFYN/A
SpS7.6
BVpS1.72
TBVpS1.72
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -15.67%
ROE -85.76%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 99.8%
FCFM N/A
ROA(3y)-8.21%
ROA(5y)-26.21%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.45%
GM growth 5Y0.15%
F-Score3
Asset Turnover0.81
Health
Industry RankSector Rank
Debt/Equity 3.12
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 49.34%
Cap/Sales 0.06%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.22
Quick Ratio 4.22
Altman-Z -5.03
F-Score3
WACC10.19%
ROIC/WACCN/A
Cap/Depr(3y)78.24%
Cap/Depr(5y)53.92%
Cap/Sales(3y)0.53%
Cap/Sales(5y)0.43%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-125.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-98.97%
EPS Next Y-122.07%
EPS Next 2Y-41.22%
EPS Next 3Y-33.62%
EPS Next 5Y-22.89%
Revenue 1Y (TTM)14.64%
Revenue growth 3Y4.27%
Revenue growth 5Y16.88%
Sales Q2Q%14.44%
Revenue Next Year3.67%
Revenue Next 2Y6.35%
Revenue Next 3Y4.21%
Revenue Next 5Y1.71%
EBIT growth 1Y30.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-9.22%
EBIT Next 3Y46.24%
EBIT Next 5YN/A
FCF growth 1Y2.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.28%
OCF growth 3YN/A
OCF growth 5YN/A

INTERCEPT PHARMACEUTICALS IN / ICPT FAQ

What is the ChartMill fundamental rating of INTERCEPT PHARMACEUTICALS IN (ICPT) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ICPT.


Can you provide the valuation status for INTERCEPT PHARMACEUTICALS IN?

ChartMill assigns a valuation rating of 2 / 10 to INTERCEPT PHARMACEUTICALS IN (ICPT). This can be considered as Overvalued.


How profitable is INTERCEPT PHARMACEUTICALS IN (ICPT) stock?

INTERCEPT PHARMACEUTICALS IN (ICPT) has a profitability rating of 2 / 10.